Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Safety and immunogenicity of hepatitis B vaccine ButaNG in adults

1999; UNIVERSIDADE DE SÃO PAULO; Volume: 41; Issue: 3 Linguagem: Inglês

10.1590/s0036-46651999000300011

ISSN

1678-9946

Autores

Luzia M. Ioshimoto, Maria Lúcia Rissato, Valentina S.J. BONILHA, Cosue Miyaki, Isaı́as Raw, Nikolai Granovski,

Tópico(s)

Hepatitis Viruses Studies and Epidemiology

Resumo

Recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan was administered in two groups of adult volunteers (I, II) following two different schedules of immunization. In the first trial (10 &mgr;g doses and 0, 1, 3 months vaccination schedule) 106 individuals completed the full immunization program. The results of seroconversion by age group varied from 70 to 100% and the GMT from 46.5 to 124.9 mIU mL-1. In the second trial with 68 individuals (for dosage comparison and 0, 1, 6 months vaccination schedule) indicated that the vaccine formulated in 20 &mgr;g was more effective than in 10 &mgr;g. The adverse reactions observed in the vaccinees were less frequent than the ones previously found since the introduction of similar vaccines.

Referência(s)